microRNA-132: a key noncoding RNA operating in the cellular phase of Alzheimer's disease.
With the consideration of the broad involvement of microRNAs (miRNAs) in the regulation of molecular networks in the brain, it is not surprising that miRNA dysregulation causes neurodegeneration in animal models. miRNA profiling in the human brain has revealed miR-132 as one of the most severely down-regulated miRNAs at the intermediate and late Braak stages of Alzheimer's disease (AD), as well as in other neurodegenerative disorders. Suppression of miR-132 aggravates multiple layers of pathology at the molecular and functional level. We describe the potential therapeutic implications of these findings and suggest miRNA targeting or replacement as a realistic multi-hit, therapeutic strategy for AD. Salta, E., De Strooper, B. microRNA-132: a key noncoding RNA operating in the cellular phase of Alzheimer's disease.
Vlaams Instituut voor Biotechnologie (VIB) Center for Brain and Disease, VIB-Leuven, Leuven, Belgium; evgenia.salta@cme.vib-kuleuven.be.|Center for Human Genetics, Universitaire Ziekenhuizen and Leuven Research Institute for Neuroscience and Disease, KU-Leuven, Leuven, Belgium; and.
Evgenia
E
Salta
Vlaams Instituut voor Biotechnologie (VIB) Center for Brain and Disease, VIB-Leuven, Leuven, Belgium; bart.destrooper@cme.vib-kuleuven.be.|Center for Human Genetics, Universitaire Ziekenhuizen and Leuven Research Institute for Neuroscience and Disease, KU-Leuven, Leuven, Belgium; and.|Institute of Neurology, University College London, London, United Kingdom.
Bart
B
De Strooper
D000544:Alzheimer Disease / Q000378:metabolism*; D002490:Central Nervous System / Q000502:physiology*; D005786:Gene Expression Regulation / Q000502:physiology*; D006801:Humans; D035683:MicroRNAs / Q000235:genetics / Q000378:metabolism*
C547077:MIRN132 microRNA, human; D035683:MicroRNAs
amyloid/TAU pathology; neurodegeneration; neuroprotection; small RNA; therapy